A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder.
about
Which anticholinergic drug for overactive bladder symptoms in adultsEfficacy and Safety of Propiverine Hydrochloride for Overactive Bladder in Adult: a Systematic Review and Meta-analysisAn overview of the clinical use of antimuscarinics in the treatment of overactive bladderα1-Adrenoceptors and muscarinic receptors in voiding function - binding characteristics of therapeutic agents in relation to the pharmacokinetics.Comparative Evaluation of the Safety and Efficacy of Long-Term Use of Imidafenacin and Solifenacin in Patients with Overactive Bladder: A Prospective, Open, Randomized, Parallel-Group Trial (the LIST Study)Add-on anticholinergic therapy for residual nocturia in patients with lower urinary tract symptoms receiving α1-blocker treatment: a multi-centre, prospective, randomised study.Vascular incontinence: incontinence in the elderly due to ischemic white matter changesExperience with imidafenacin in the management of overactive bladder disorderLong-term safety, efficacy, and tolerability of imidafenacin in the treatment of overactive bladder: a review of the Japanese literature.Associations between subjective overactive bladder symptoms and objective parameters on bladder diary and filling cystometry.A Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia, and Subjective Sialorrhea: A Systematic Review Sponsored by the World Workshop on Oral Medicine VI.The medical treatment of overactive bladder, including current and future treatments.Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature.Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females.Propiverine: a review of its use in the treatment of adults and children with overactive bladder associated with idiopathic or neurogenic detrusor overactivity, and in men with lower urinary tract symptoms.Imidafenacin for the treatment of overactive bladder.Cardiovascular effects of antimuscarinic agents in overactive bladder.Innovative pharmacotherapies for women with overactive bladder: where are we now and what is in the pipeline?Efficacy and safety of imidafenacin for overactive bladder in adult: a systematic review and meta-analysis.World Workshop on Oral Medicine VI: a systematic review of medication-induced salivary gland dysfunction.Delivery methods for drugs used in the treatment of overactive bladder.Potential Primary Endpoint for Exploratory Clinical Trial in Patients with Overactive Bladder: A Systematic Literature Review.Prospective analyses of female urinary incontinence symptoms following total hip arthroplasty.Clinical Guideline for Female Lower Urinary Tract Symptoms.Characterization of bladder selectivity of antimuscarinic agents on the basis of in vivo drug-receptor binding.A randomised, double-blind, parallel design, multi-institutional, non-inferiority phase IV trial of imidafenacin versus fesoterodine for overactive bladder.Efficacy and safety of once-daily oxybutynin patch versus placebo and propiverine in Japanese patients with overactive bladder: A randomized double-blind trial.Factors influencing patient satisfaction with antimuscarinic treatment of overactive bladder syndrome: results of a real-life clinical study.Long-term safety and efficacy of two different antimuscarinics, imidafenacin and solifenacin, for treatment of overactive bladder: a prospective randomized controlled study.Indirect treatment comparison (ITC) of medical therapies for an overactive bladder.A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms.Effect of imidafenacin on nocturia and sleep disorder in patients with overactive bladder.Correlation between improvements in Overactive Bladder Symptom Score and health-related quality of life questionnaires in overactive bladder patients treated with an antimuscarinic drug.Cognitive Safety and Overall Tolerability of Imidafenacin in Clinical Use: A Long-Term, Open-Label, Post-Marketing Surveillance Study.Clinical efficacy and safety of mirabegron and imidafenacin in women with overactive bladder: A randomized crossover study (the MICRO study).Results of a randomized, double-blind, active-controlled clinical trial with propiverine extended release 30 mg in patients with overactive bladder.Urinary Excretion Contributes to Long-Lasting Blockade of Bladder Muscarinic Receptors by Imidafenacin: Effect of Bilateral Ureteral Ligation.Optimum Dose of Once-Daily Oxybutynin Patch in Japanese Patients with Overactive Bladder: A Randomized Double-Blind Trial Versus Placebo.Propiverine hydrochloride in Japanese patients with overactive bladder: a randomized, double-blind, placebo-controlled trial.A randomised, prospective double-blind, propiverine-controlled trial of imidafenacin in patients with overactive bladder.
P2860
Q24203880-A64E5696-BAD9-473B-8589-90547F0AD046Q28067504-2E623AFF-53D7-4E39-B8F4-636F8EC28F32Q35042575-73D25765-F7E1-4019-9189-DFFEB84F0C66Q35183611-3E0C1F74-250F-446E-8159-B11A8BC05F3AQ35419834-889C977A-9AEF-40DE-B197-4139EE05B6A3Q36012645-8D562B04-23D3-4854-9B94-B83EE5B646EFQ36375655-1343B80F-3905-4F75-A0A8-90562AEFFC68Q36541100-DE7F3FAD-104C-4187-954A-643FBDB44EF0Q36587687-7233267C-453F-45C2-AA07-C1EE355EAA2FQ36668261-9784A78A-9ABC-450C-9D56-EB708EA6AA62Q37653402-B6FC98CF-9C0D-4CB2-9270-246FC90A8CD8Q37836943-017FDC7B-4FC7-4A30-B583-3D36E5A1BB36Q37864717-E120823B-9A09-42A0-91C2-9713EC87DE28Q38032608-8C999DA9-C30D-4A01-B946-5CF728F5BF72Q38071594-868652F7-DDCB-475E-9F33-858F8E63F69BQ38103894-A1A38623-653C-49A1-BAC8-3BA254D1BE78Q38116972-CE56DF63-F01E-40DE-94AF-C0BCB4AF6E29Q38265873-23E0DFAF-3178-4BB8-A0A3-2B52A4372EE1Q38338125-97E137DD-BC62-4672-BFEE-29DAC1B7B5E1Q38646237-1219AE2D-672C-40D1-9FD9-14149A1409ECQ38665319-ED5AB244-8890-4C73-A3FD-6CD4A50E436EQ38993756-C878AB52-897D-4B03-81C7-3C0C54DDE2B4Q39380294-0BBF5D88-52A8-43E5-B00C-72B1D472FAA4Q40963346-0D77A739-5A08-4682-A5C3-AC07E5A0FE07Q42428489-F3B9B176-01E5-40A0-9C8A-0CAFA7A5D4EFQ44458229-A325E121-D107-428F-A5B0-5224CB5B8015Q44777025-AD2DAAED-231F-4511-9126-8BAA76724AD0Q44874780-F0C36130-7735-4A99-8D1A-B07BB0FAA591Q46351979-399633F0-76D2-47D0-9A60-ACFB21C4A030Q47433658-FF6110D8-A20D-4361-BDFD-4416FBF84ADDQ47843776-C99BB3D4-9BEB-4ACE-837D-FD3DC1898ACFQ48231452-315A9F8A-79A4-4B6D-B373-8B5747FF805DQ48673293-51CBBD2B-1A89-42FF-AECB-484864614BA5Q50625165-C2263BEC-71B9-4A2A-A6CC-02CC3A91B74BQ50890665-CA392146-BDBA-46BD-A841-4F5200C9200AQ50907877-ACCC733E-1B4C-46B3-8459-7322B44A935AQ51070112-F77053AA-8A3A-4191-B83E-504677AA1B3FQ51166031-E964FFB1-E30D-40F9-BEB7-D929EE966223Q53049443-849F7C8E-F19B-47B5-8C88-D4AE41C96E07Q54391945-EBCB7EB9-9D5A-40EF-8211-F6661554F8C2
P2860
A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
A randomized, double-blind, pl ...... ients with overactive bladder.
@en
A randomized, double-blind, pl ...... ients with overactive bladder.
@nl
type
label
A randomized, double-blind, pl ...... ients with overactive bladder.
@en
A randomized, double-blind, pl ...... ients with overactive bladder.
@nl
prefLabel
A randomized, double-blind, pl ...... ients with overactive bladder.
@en
A randomized, double-blind, pl ...... ients with overactive bladder.
@nl
P2093
P2860
P1476
A randomized, double-blind, pl ...... ients with overactive bladder.
@en
P2093
Imidafenacin Study Group
Osamu Yamaguchi
Yukio Homma
P2860
P304
P356
10.1111/J.1442-2042.2009.02286.X
P577
2009-03-29T00:00:00Z